Glionova Therapeutics secures $5.7 million to take glioblastoma therapy into clinic
“We welcome this significant support from our new as well as existing investors, who represent some of the most experienced in the global life sciences industry,” said Eugen Steiner, M.D., Ph.D., Chief Executive Officer of Glionova Therapeutics. “Their combined experience and financial backing will enable us to advance GLN-1001 into clinical development with the aim of making it available for patients with glioblastoma.“
Glionova Therapeutics is developing GLN-1001, a novel agent for potential disease modifying treatment for glioblastoma, the most common and most aggressive form of brain cancer. The project is based on recently published research from the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet and the Swedish national research infrastructure organisation Chemical Biology Consortium Sweden (CBCS), and the market opportunity identified by KI Innovations.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.